Abstract. Hepatocellular carcinoma (Hcc) is one of the most common, aggressive malignancies with poor prognosis and high mortality. Although great progress has been made in recent decades, overall survival of Hcc patients remains unsatisfactory due to high recurrence and metastasis. Accordingly, understanding and clarifying the underlying molecular mechanisms of metastasis has become increasingly important. Recently, accumulated reports have supported that long noncoding RNAs (lncRNAs) are dysregulated in Hcc and are involved in various pivotal biological processes, including metastasis. The aim of this review was to investigate the dysregulation of lncRNAs in Hcc and their function as oncogenes or tumour suppressors. Furthermore, reciprocal regulatory networks between lncRNAs and various molecules that were identified in HCC metastasis, including regulating epithelial-mesenchymal transition (EMT), controlling metastasis-associated genes, and regulating tumour angiogenesis were examined. Numerous reports and information on lncRNAs may help identify lncRNAs that are potential novel diagnostic markers, prognostic markers and therapeutic targets.

Contents

1. Introduction
2. lncRNAs are aberrantly expressed in HCC
3. lncRNAs and EMT
4. lncRNAs and HCC metastasis-associated genes
5. lncRNAs and angiogenesis
6. Conclusion and future perspectives

1. Introduction

Hepatocellular carcinoma (HCC) is one of the most common, aggressive malignancies and a frequent cause of cancer-related mortality worldwide, especially in many Asian and African countries (1,2). The high recurrence rate of HCC is mainly due to the spread of intrahepatic metastasis (3,4). Metastasis is a complex and multistep process. In this process, tumour metastasis-related gene abnormalities, epithelial-mesenchymal transition (EMT), and tumour microenvironment alterations, such as angiogenesis, are believed to be important for the metastasis process (5). However, the underlying molecular mechanisms that mediate the metastatic cascade remain unclear. Recently, accumulated evidence suggests that long noncoding RNAs (lncRNAs) may play a crucial role in the metastasis process of HCC.

lncRNAs are defined as RNA molecules with a length of 200-100,000 bp that lack protein-coding potential (6,7). lncRNAs have been reported to be involved in gene regulation, including transcriptional and post-transcriptional regulation, epigenetic regulation, and siRNA-directed gene regulation (8). Hundreds of lncRNAs have been identified (http://rfam.xfam.org) by computational predictions, and some of them have been experimentally verified and show tissue-specific expression (9-11). Moreover, these novel lncRNAs were elucidated to be involved in some pivotal biological processes, including cell growth, proliferation, apoptosis and metastasis and angiogenesis (12). In addition, recent evidence suggests that some HCC-related lncRNAs can act either as oncogenes or tumour suppressor genes, and expression profiling has revealed characteristic lncRNA signatures in HCC (13,14). Similarly, some HCC-related lncRNAs have been suggested to be useful as novel potential markers for HCC diagnosis and prognosis (15). This review focused on the relationship between lncRNAs and EMT, HCC metastasis-related genes and tumour angiogenesis and highlights many pathways of lncRNAs involved in these processes.

2. lncRNAs are aberrantly expressed in HCC

Gene expression profiling analyses have shown that numerous lncRNAs are dysregulated in HCC cell lines or cancer tissues compared with liver normal cell lines or matched normal
liver tissue (16,17). Importantly, some of these aberrantly expressed lncRNAs have been confirmed to be associated with hepatocarcinogenesis (18,19). In addition, lncRNA expression signatures were correlated with clinicopathological characteristics of HCC, such as metastasis and prognosis (20,21). In the present review, the aberrant expression of lncRNAs and their biological roles in HCC were summarized (Table I).

Among the upregulated lncRNAs, highly upregulated in liver cancer (HULC) was identified and reported by more than one study. As Fig. 1A shows, HULC, as an oncogene, promotes tumorigenesis by controlling multiple pathways, such as upregulation of HMG2A expression (13), promotion of EMT via miR-200α-3p (22), promotion of abnormal lipid metabolism via RXRA (23), and upregulation of sphingosine kinase 1 (SPHK1) expression to promote tumour angiogenesis (24). The reports indicated that these signalling pathways broadly interact with each other and highlight the complexity of gene regulation by lncRNAs. Interestingly, HULC was also upregulated in other cancer types, including gastric cancer, osteosarcoma, pancreatic cancer and breast cancer (25). The aforementioned studies suggested that HULC plays an important pathogenic role and clinical value in human cancer. Among the downregulated lncRNAs, as shown in Fig. 1B, maternally expressed gene 3 (MEG3), as a tumour suppressor, inhibits tumorigenesis and progression by regulating multiple pathways, such as the MEG3/miR-664/ADH4 (14) and DNMT1/MEG3/P53 axes (26,27). Taken together, these data indicate that dysregulation of lncRNAs results in abnormal expression of target genes and activity of signalling pathways, eventually leading to tumorigenesis and metastasis.

3. lncRNAs and EMT

Epithelial-mesenchymal transition. Epithelial-mesenchymal transition (EMT) is a highly conserved molecular reprogramming process that causes polarized immotile epithelial cells to change to motile mesenchymal cells (28). This process was initially recognized during embryonic development and was implicated in the early events of tumour cell metastasis by endowing cells with a more motile, invasive potential (29,30). EMT is mediated by key transcription factors, including zinc-finger E-box-binding (ZEB), SNAIL, and basic helix-loop-helix (bHLH) transcription factors (31). These key transcription factors are regulated at the transcriptional and translational levels. In addition to EMT transcription factors, different signalling pathways have leading roles in the initiation and progression of EMT (32). Thus, lncRNAs may play a crucial role in EMT progression.

lncRNAs regulate EMT transcription factors and direct targets. lncRNAs that selectively bind mRNAs, miRNAs, and proteins, thus inhibiting their transcription, promoting their degradation or suppressing their translation, also regulate EMT progression (6,33). A decrease in E-cadherin expression is considered a crucial step and fundamental event in the progression of EMT. We know that SNAIL and ZEB transcription factors, as EMT drivers, can bind to and repress the activity of the E-cadherin promoter, leading to EMT (31,34). Accumulated evidence has shown that some lncRNAs control the expression of EMT master transcription factors. A schematic model and regulatory network of lncRNA functions during the process of EMT were summarized and generated (Fig. 2). For example, lncRNA-ATB and lncRNA HULC upregulated ZEB1 and ZEB2 expression by competitively binding miR-200α; hence, lncRNA-ATB and lncRNA HULC depletion or the loss of ZEB by siRNA can reverse EMT and inhibit HCC invasion and metastasis (22,35). Additionally, lncRNA CCAT2, as an oncogene, promotes SNAIL2 and ZEB1 expression, and decreased expression of E-cadherin leads to EMT (36,37). Interestingly, lncRNA CCAT2 can promote HCC progression by competitively binding to miR-34a and upregulating FOXM1 expression while FOXM1 binds to the CCAT2 promoter to activate its transcription, resulting in a double-positive feedback loop between CCAT2 and FOXM1 (38). SNHG20 promoted ZEB1/2 and N-cadherin expression and downregulated E-cadherin expression in HCC by binding to enhancer of zeste homolog 2 (39). A similar regulatory mechanism also exists between SPRY4-IT1 and EZH2 and E-cadherin (40).

UCAL upregulation promotes the translation of SNAIL2 mRNA and induces EMT progression in HCC by effectively sponging miR-203. MiR-203 and SNAIL2 regulation is a double-negative feedback loop, with miR-203 suppressing SNAIL2 expression and SNAIL2 protein repressing the expression of miR-203 (41). During EMT, increased HULC or UBE2C3 expression results in upregulation in SNAIL1 levels and EMT progression (42,43). Additionally, lncRNA-MUF overexpression accelerated EMT progression by binding Annexin A2 and activating the Wnt/β-catenin pathway. lncRNA-MUF functions as a competing endogenous RNA for miR-34a, leading to SNAIL1 upregulation and EMT activation (44). Finally, SNAIL2, as a target of miR-140-5p (which induces EMT in HCC cells), is upregulated by Unigene56159 in HCC (45).

Apart from regulating EMT transcription factor expression, lncRNAs target genes that encode adhesion junction and polarity complex proteins and signalling mediators. For example, high levels of lncRNA UBE2C3, which are related to poor prognosis in HCC patients, inhibit E-cadherin expression but enhance SNAIL1 and N-cadherin expression and promote EMT progression by increasing HCC cell invasion and migration (43). Similarly, high levels of PVT1 promote HCC cell EMT progression by repressing E-cadherin expression (46). Conversely, lncRNA-p21 inhibits HCC invasion and metastasis through the miR-9/E-cadherin cascade signalling pathway (47). N-cadherin expression is repressed by SNHG20, the expression of which is positively associated with larger tumour size and is negatively correlated with OS in HCC patients. Additionally, decreased SNHG20 expression in HCC cells results in increased N-cadherin expression levels and induces EMT progression (39). During EMT, high expression of ZEB2 AS1, which was correlated with tumour metastasis in HCC, enhanced HCC metastasis by regulating ZEB2, E-cadherin and N-cadherin expression (48).

Several lncRNAs could repress the expression of the intermediate filament protein vimentin, which changes the normal cytoskeleton structure, to inhibit HCC cell EMT progression and metastasis. Among these, lncRNA-Dreh, which is downregulated by HBx, targets vimentin mRNA, resulting in decreased vimentin expression and reduced dissolution of tight
junctions, to block EMT (49). Vimentin is also controlled by lncRNA AOc4P and lncRNA GAS5, both of which are tumour suppressors that bind to vimentin and promote its degradation and therefore inhibit HCC invasion and metastasis (50,51). Additionally, CASC2 could inhibit HCC cell invasion and EMT progression by targeting the miR-367/FBXW7 axis, and lncRNA-p21 decreased EMT and metastasis by targeting Notch (52). Clearly, abnormal expression and activities of lncRNAs represent an extensive regulatory network by changing the gene expression programme to control EMT progression.

lncRNAs mediate control of EMT signalling pathways. Long noncoding RNAs are commonly known as potential gene expression modifiers that alter several phases of expression, including transcription, post-transcriptional processing, translation, and epigenetic regulation (6). Recently, the number of known lncRNAs that have been directly or indirectly associated with EMT signalling pathways has become extensive (Fig. 3). Multiple signalling pathways trigger EMT in the initiation and progression of tumour metastasis, including the transforming growth factor-β (TGF-β) family, Wnt/β-catenin, Notch, EGF, HGF, FGF, and HIF. Among these pathways, the TGF-β signalling pathway has a predominant role, but the others are also required. Most importantly, the convergence of these signalling pathways is essential for EMT (53).

As the role of TGF-β-induced EMT in cancer cell dissemination is well established, Yuan et al reported that lncRNA-ATB promotes HCC cell metastasis by competitively binding miR-200a, upregulating ZEB1 and ZEB2, and then inducing EMT (35). Notably, several similar reports in other tumour types (lung cancer, breast cancer and endometrial carcinoma) have been reported. For example, Li et al showed that MALAT1 expression was increased by TGF-β induction,

| Table I. Dysregulation of lncRNAs and biological function in HCC. |
|----------------|----------------|---------------------------------|
| lncRNAs | Dysregulation | Biological function in HCC | (Refs.) |
| HULC | Upregulation | Promote tumorigenesis and metastasis. Associated with HBV infection. As a prognosis biomarker | (10,13,18,20,22-25) |
| MALAT1 | Upregulation | Promote HCC growth, motility, metastasis | (69,70-73) |
| HOTAIR | Upregulation | Promote cell invasion, metastasis. As a diagnosis, recurrence and prognosis biomarker | (64-66) |
| HOTTIP | Upregulation | Promote tumorigenesis and progression. Associated with disease outcome | (21) |
| HEIH | Upregulation | Associated with HBV-related HCC. As a recurrence and prognosis biomarker | (42) |
| PCAT-1 | Upregulation | Promote cell proliferation and invasion, metastasis. Associated with prognosis | (80) |
| PVT1 | Upregulation | Promote cell proliferation, cell cycling. Associated with prognosis | (46) |
| ATB | Upregulation | Promote HCC metastasis | (35) |
| CCAT1 | Upregulation | Promote cell proliferation and migration | (78) |
| CCAT2 | Upregulation | Regulate cell proliferation, migration, apoptosis, metastasis, associated with prognosis | (36-38) |
| SNHG20 | Upregulation | Promote cell invasion. Associated with prognosis | (39) |
| SPRY-4-IT1 | Upregulation | Promote cell proliferation and invasion. As a diagnosis biomarker | (40) |
| UCA1 | Upregulation | Promote HCC growth, metastasis and associated with prognosis | (41) |
| TCF7 | Upregulation | Promote HCC progression by EMT and Wnt signaling | (62) |
| ZFAS1 | Upregulation | Associated with intrahepatic and extrahepatic metastasis and poor prognosis of HCC | (61) |
| ZEB1-AS1 | Upregulation | Promote HCC metastasis and predict poor prognosis | (79) |
| ZEB2-AS1 | Upregulation | Promote tumor growth and metastasis. Associated with prognosis | (48) |
| MVIH | Upregulation | Promote HCC growth and intrahepatic metastasis, associated with prognosis | (78) |
| MEG3 | Downregulation | Inhibit cell proliferation. Associated with prognosis and methylation | (14,26,27,99,100) |
| lncRNA-P21 | Downregulation | Inhibit HCC cell invasion and metastasis | (47,60) |
| CPS1-IT1 | Downregulation | Inhibit HCC metastasis | (63) |
| GAS5 | Downregulation | Associated with prognosis, suppress cell proliferation and invasion | (51,82-84) |
| XIST | Downregulation | Inhibit HCC cell proliferation and metastasis | (87-92) |
| lncRNA-LET | Downregulation | As a regulator of hypoxia signaling, inhibit HCC invasion | (81,107) |
| FTX | Downregulation | Inhibit cell proliferation and metastasis. Promote cell proliferation | (85,86) |
and the miR-200c/MALAT1 axis could inhibit the expression of EMT-associated proteins in endometrial carcinoma (EEc) and subsequently repress EMT progression. Once the interaction between miR-200c/MALAT1 was interrupted, EMT marker expression was altered, and the TGF-β signaling pathway was activated (54). Findings of a previous study
showed that lnc00673 activated by TGF-β induced EMT, promoted lung cancer cell invasion by inhibiting miR-150-5p expression, and then upregulated ZEB1 to finally induce EMT progression (55). Additionally, studies with similar regulatory mechanisms were also reported (56,57).

The WNT signalling pathway promotes EMT, and β-catenin-mediated gene expression is increased in tumour cells and tissues. lncRNA-MUF is highly expressed in HCC. Decreased lncRNA-MUF expression repressed EMT; conversely, lncRNA-MUF overexpression accelerated EMT progression. Mechanistic investigations suggested that lncRNA-MUF combined with Annexin A2 to activate Wnt/β-catenin and EMT. In addition, lncRNA-MUF can bind to miR-34a, leading to Snail1 upregulation and EMT activation (44).

The activation of EMT by receptor tyrosine kinases (RTKs) highlights the roles of the PI3K-AKT and MAPK pathways in this transitional process. MAPK pathway activation by not only growth factors but also mutations in the genes encoding RAS or RAF, also contributes to EMT. lncRNA NNT-AS1 promoted CRC cell migration and invasion by activating the ERK/MAPK pathway and EMT (58). lncRNA BC087858 could promote cell invasion by activating the PI3K/AKT and MEK/ERK pathways and EMT by upregulating ZEB1 and Snail expression in NSCLC (59).

The Notch signalling pathway also triggers EMT. Overexpression of lincRNA-p21 inhibited Notch signalling and EMT, while its downregulation led to the reverse result (60). Upregulation of ZFAS1 expression in glioma tissues was significantly associated with poor overall survival. EMT and the Notch signalling pathway were inhibited in glioma cells after ZFAS1 knockdown. Therefore, ZFAS1 could exhibit an oncogenic role by regulating EMT and the Notch signalling pathway (61).

Activation of the HIF-α/STAT3 signalling pathway also switches on the EMT process. lncRNA-ATB promoted the colonization of disseminated tumour cells to organs by binding IL-11 and triggering STAT3 signalling (35). IL-6 could induce lncTcF7 expression in HCC cells by activating STAT3. Importantly, knocking down STAT3 and repressing STAT3 activation reduced lncTcF7 expression; as a result, decreased lncTcF7 prevented IL-6-induced EMT (62). Decreased expression of CPS1-IT1 was significantly correlated with poor prognosis. CPS1-IT1 acts as a tumour suppressor in HCC by decreasing HIF-1α activation and inhibiting the EMT process (63). Another report describes HOTAIR and RCC metastasis. The results showed that HOTAIR promotes RCC tumorigenesis and metastasis via miR-217/HIF-1α/AXL signalling both in vitro and in vivo (64).

Clearly, these intricate networks are closely connected, and changes in any of these networks have a profound effect on other networks. Once the network of balance is disrupted, one or several signalling pathways may be switched on and activated, finally leading to EMT or MET.

4. lncRNAs and HCC metastasis-associated genes

The role of lncRNAs either as oncogenes or tumour suppressors. The role of lncRNAs either as oncogenes or
tumour suppressors in human cancers, including HCC, has been previously established. Genome-wide transcriptomic analyses have identified a series of metastasis-associated genes, and their aberrant expression in primary HCC correlates with metastasis and poor prognosis. Recently, an increasing number of IncRNAs associated with metastasis based on IncRNA profiling of early-stage versus advanced HCC tissues have been identified and verified as upstream regulators of metastasis-associated genes. For the present review, the available evidence on these IncRNAs in HCC was summarized.

**Pro-metastatic IncRNAs regulate HCC invasion and metastasis.** High expression of HOX transcript antisense RNA (HOTAIR) in human breast cancer was first reported by Gupta et al (65). Overexpression of HOTAIR promoted cancer cell metastasis in vitro and in vivo. Following investigation of the mechanism, they reported that HOTAIR is selectively required to target polycomb repressive complex 2 (PRC2) and induce methylation of histone H3 on lysine 27 (H3K27me3), resulting in the downregulation of multiple metastasis suppressor genes, including HOXD10 and many others. Moreover, HOTAIR is highly expressed in breast cancer tissues, and upregulation of HOTAIR expression in primary breast cancer is a powerful predictor of prognosis (65). Similarly, HOTAIR is correlated with tumour size and lymph node metastasis in HCC. Knockdown of HOTAIR decreases matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor (VEGF) expression, which play an important role in metastasis (66). The HOTAIR/PRC2/H3K27me3/HOXD axis is a classic example of metastasis-related interplay between IncRNAs and cancer metastasis-associated genes.

As described previously, HOXD may be a key IncRNA in the cancer metastatic pathway. IncRNA HOXD-AS1 is transcribed in the antisense orientation of the protein-coding gene HOXD1. IncRNA HOXD-AS1 functions as an oncogene and can promote cell invasion and metastasis by affecting signalling pathways in various cancer cell lines. Global gene expression analysis revealed that HOXD-AS1 upregulation was associated with poor prognosis in HCC patients and may represent an independent prognostic biomarker in HCC. Mechanistically, the transcription factor STAT3 could activate the transcription of HOXD-AS1, which protects SOX4 against miRNA-mediated degradation and thus activates the expression of EZH2 and MMP2 to facilitate HCC metastasis (67). Lu et al reported that HOXD-AS1 promotes HCC metastasis and that its pro-metastatic phenotype can partially be attributed to the HOXD-AS1/miR-19a/ARHGAP11A signalling axis (68). Accordingly, the HOTAIR/PRC2/H3K27me3/HOXD, HOXD-AS1/miR-130a-3p/SOX4/EZH2 and MMP2 and HOXD-AS1/miR-19a/ARHGAP11A signalling pathways form a cascade effect for HCC metastasis (Fig. 4).

Yuan et al found that upregulated expression of IncRNA-activated by TGF-β (IncRNA-ATB) in HCC could induce EMT and promote the invasion-metastasis cascade of HCC cells in vivo. Mechanistically, they reported that IncRNA-ATB promotes HCC metastasis by functioning as a ceRNA for the miR-200 family that targets ZEB1 and ZEB2, which induces EMT. The miR-200 family regulates EMT by targeting ZEB1 and ZEB2, and EMT facilitates tumour invasion and dissemination. However, Yuan and colleagues (35) also found that IncRNA-ATB promoted HCC cell metastasis, which was not completely dependent on the miR-200 family. This suggested that metastasis is determined not only by the miR-200-ZEB-EMT axis, but also by an additional downstream player of IncRNA-ATB. Indeed, IncRNA-ATB promotes HCC cell colonization by binding IL-11, causing autocrine induction of IL-11 secretion and consequent activation of STAT3 signalling (35). Thus, IncRNA-ATB plays a pro-metastatic role in HCC. The expression of IncRNA-ATB was increased in HCC, breast cancer, colorectal cancer and gastric cancer cell lines. Accordingly, activity of the IncRNA-ATB/miR-200/ZEB and IncRNA-ATB/IL-11/STAT3 pathways finally leads to HCC tumorigenesis and metastasis.

The long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), the expression of which is upregulated in lung cancer tissues and cells, is a critical regulator of the metastasis phenotype of lung cancer (9). Similarly, findings have shown that MALAT1 is a pro-metastatic IncRNA in HCC invasion and metastasis. First, the level of MALAT1 expression correlated significantly with advanced clinical stage, metastasis and poor prognosis in HCC. Moreover, MALAT1 was found to promote HCC cell invasion and metastasis both in vitro and in vivo (69). In addition, many targets of MALAT1, which include some metastasis-associated genes that directly or indirectly regulate HCC metastasis, have been identified by computational predictions, and some of them have been experimentally verified (Fig. 5). Transforming growth factor β-binding protein 3 (LTBP3), which has been identified as a target gene of MALAT1, could promote HCC cell migration and invasion, which could also be upregulated by HBx. Mechanistically, one group found that HBx could upregulate MALAT1 and that MALAT1 could further activate the expression of LTBP3, resulting in the promotion of HCC metastasis (70). EGFR is also an important target of MALAT1, not only because EGFR is a validated driver gene and an important protein in tumour metastasis, but also because EGFR can promote the PI3K/AKT and JAK/STAT signalling pathway activity. Mechanistically, MALAT promotes HCC metastasis by targeting miR-195-mediated EGFR phosphorylation (71). Similar to EGFR, ZEB1 and TRAF6 (as targets of MALAT1 mediated by miR-143-3p and miR-146-5p) promote HCC metastasis (72,73). Aside from its role in regulating downstream genes, MALAT1 is regulated by several tumour metastasis-associated genes. TGF-β, c-MYC, and HIF-2α could induce or activate the expression of MALAT1 by different molecular mechanisms (74-76). With the reciprocal positive feedback loop between MALAT1 and EZH2 or HIF-2α, these upstream regulators and downstream targets, such as EGFR, ZEB1, LEBP3 and TRAF6, compose a complex network to regulate HCC metastasis.

Recently, several other IncRNAs were proposed to promote HCC growth and metastasis. Yang et al reported that a high IncRNA expression in HCC was significantly associated with recurrence and is an independent prognostic factor for survival. IncRNA-HEIH promotes HCC growth by targeting enhancer of zeste homolog 2 (EZH2) (77). Moreover, IncRNA-MVIH (IncRNA associated with microvascular invasion in HCC) can also regulate HCC growth and intrahepatic metastasis by inhibiting the secretion of phosphoglycerate kinase 1 (PGK1).
CCAT1 promotes HCC progression by functioning as a let-7 sponge and leads to release of the repression of its endogenous targets HMGA2 and c-Myc (78). Another pro-metastatic lncRNA, ZEB1-AS1, is frequently upregulated in HCC, especially in metastatic HCC tissues. ZEB1-AS1 acts as an oncogene in HCC and promotes tumour growth and metastasis by positively regulating ZEB1 expression (79). PcAT-1 can promote HCC cell proliferation and viability by targeting the kinase cRK-like proto-oncogene adaptor protein (cRKL), and, in turn, PcAT-1 is regulated by miR-215, a P53-inducible miRNA. Therefore, the TP53-PcAT-1-cRKL axis may be an important regulatory pathway in HCC (80). Taken together, the data regarding these pro-metastatic lncRNAs and their targets suggest the existence of a complex network controlling HCC growth and metastasis.

Anti-metastatic lncRNAs regulate HCC invasion and metastasis. Yang et al. (81) showed that lncRNA low expression in tumour (lncRNA-LET) was downregulated in HCC and confirmed it as a positive regulator of HCC metastasis. Those authors reported that hypoxia-induced histone deacetylase 3 (HDAC3) expression inhibits lncRNA-LET by decreasing the histone acetylation-mediated regulation of the lncRNA-LET promoter region. Then, lncRNA-LET was bound to target gene-nuclear factor 90 protein (NF90), which increases NF90 degradation by the proteasome. Finally, low lncRNA-LET expression contributes to hypoxia-induced HCC cell invasion (81).

Another metastasis suppressor, lncRNA GAS5, was found to be downregulated in HCC tissues compared to adjacent normal tissues. Moreover, a decreased expression of GAS5 was significantly correlated with differentiation and portal vein tumour metastasis and was an independent predictor for overall survival. In addition, it was demonstrated that GAS5 suppressed proliferation and invasion in HCC by negatively regulating vimentin expression (51). GAS5 was downregulated in other cancers, and restoring its expression significantly inhibited cancer progression. EZH2, miR-21 and miR-222 were further verified as GAS5 target genes, and knocking down these genes can reduce the in vitro invasive ability and in vivo metastatic potential (82-84). The downregulation of long noncoding RNA FTX (Inc-FTX) was also found in HCC. Lnc-FTX can inhibit HCC cell epithelial-mesenchymal transition and invasion by physically binding miR-374a and MCM2 (85). Of note, Furlan et al. reported that Inc-FTX is required in cis to promote XIST transcriptional activation and establishment of X chromosome inactivation (XCI) (86).

The long noncoding RNA XIST downregulation in HCC was first reported by Zhuang et al. They stated that XIST is one of the tumour suppressing lncRNAs that can inhibit HCC cell proliferation and metastasis. XIST and its target miR-92b directly interacted with and repressed each other (87). Similar results have also been reported: miR-181a and miR-194-5p promoted HCC progression by targeting PTEN and MAPK1, and both were mediated by the long noncoding RNA XIST (88,89). Moreover, a decrease in the expression of long noncoding RNA XIST is associated with the prognosis of HCC. These results suggest that lncRNA XIST functions as a tumour suppressor to inhibit oncogene expression in hepatocellular carcinoma. Notably, lncRNA XIST has also been found to be dysregulated in other cancers, such as gastric (90), colorectal (91), and oesophageal cancer (92). However, those reports showed that XIST expression was upregulated in these cancers and functions as an oncogene. For example, Chen et al. (91) reported that lncRNA XIST was overexpressed in colorectal cancer and that upregulation of lncRNA XIST promoted metastasis and modulates EMT in colorectal cancer by competing for miR-200b to regulate ZEB1 expression. Other research has shown that XIST promotes oesophageal squamous cell carcinoma by regulating miR-101/EZH2 (92). In addition, XIST was found to promote cell invasion by regulating the miR-497/MACC1 axis in gastric cancer and was associated with the prognosis of these patients (90). Consequently, XIST, miRNAs and oncogenes...
or tumour suppressors interact to create a large regulatory network. Once one of the genes was disrupted, the levels of the associated genes were changed; therefore, the entire network was broken.

5. IncRNAs and angiogenesis

Tumour angiogenesis is considered a crucial step and one of the cornerstones for helping to sustain expanding neoplastic growth (5). In this regard, HCC is one of the most vascular solid tumours with a high tendency for vascular invasion (93). A compelling body of evidence indicates that the angiogenesis switch is triggered by cellular stress factors such as hypoxia, the activation of oncogenes such as RAS and C-MYC or the activation of tumour suppressors, such as P53. One of the well-known regulatory pathways of angiogenesis is via signalling proteins that bind to cell-surface receptors demonstrated by vascular endothelial cells, such as VEGF and FGF (94). VEGF gene expression is induced and upregulated by hypoxia through hypoxia inducible factor-1 (HIF-1), which in turn activates VEGFR2 to stimulate cell migration and to initiate angiogenesis. The role of VEGF in the formation and development of neovascularization in HCC has been extensively reported and established in the process between the early and advanced stage of HCC. Furthermore, VEGF correlates with HCC progression, metastasis, a tendency towards portal invasion and a higher recurrence rate (95). Moreover, current clinical practice shows extensively established and accepted VEGFR-targeted therapies for patients with advanced HCC, such as the multi-kinase inhibitor sorafenib, which is well known to inhibit the kinase activities of VEGFR and PDGFR (96).

Recently, accumulating evidence has shown that aberrantly expressed IncRNAs could be linked to cancer-associated angiogenesis (Fig. 6). Fu et al reported that the upregulation of HOTAIR promoted tumour cell growth and angiogenesis by directly activating VEGFA and Ang2 expression (97). A similar result was also reported: HOTAIR could enhance angiogenesis by inducing VEGFA expression in glioma cells (98). Su et al found that MEG3 was downregulated and inversely associated with VEGF expression levels in osteoarthritis (99). Therefore, HOTAIR and MEG3 may play a major role in the control of angiogenesis. Next, a report demonstrated that MEG3 could regulate angiogenesis through activation of the p53/NOX4 axis, which would downregulate HIF-1α and VEGF expression (100). Furthermore, upregulation of IncRNA TUG1 in hepatoblastoma promotes tumour growth and angiogenesis by enhancing the expression of VEGFA, which is regulated by miR-34a-5p (101). IncRNA-MIAT was able to promote endothelial cell proliferation, migration, and tube formation by increasing the expression of VEGF via direct binding to miR-150-5p (102). Additionally, a previous report indicated that MALAT1 could promote angiogenesis and immunosuppressive properties of mesenchymal stem cells by inducing VEGF and IDO expression (103). Zha et al demonstrated that HULC could promote angiogenesis in human gliomas by regulating ESM-1 via the PI3K/Akt/mTOR signalling pathway (104). Furthermore, IncRNA associated with microvascular invasion in hepatocellular carcinoma (IncRNA MVIH) is well known to play an important role in HCC by inducing angiogenesis. IncRNA MVIH could activate tumour-inducing angiogenesis by repressing the secretion of PKG1 and increasing microvessel density in hepatocellular carcinoma (78).

Another well-known switch of angiogenesis is hypoxia. Under hypoxic conditions, angiogenesis can be activated by a family of transcription factors known as hypoxia inducible factors (HIFs), such as HIF-1. Dysregulation of HIF-1 expression is associated with tumour metastasis and poor clinical outcome in HCC (105). In recent years, a series of hypoxia-induced IncRNAs, such as HOTAIR, MALAT1, and PVT1, have been identified using RNA expression profiling and high-throughput approaches. Based on RNA expression profiling data, Takahashi et al identified 89 differentially expressed IncRNAs in HepG2 HCC cells under hypoxic conditions; 20 IncRNAs were upregulated by at least a 2-fold change, while 11 were downregulated under hypoxic conditions. Those authors further confirmed that IncRNA-RoR, as an oncogene, could drive tumour growth via the IncRNA-RoR/miR-145/HIF-1α axis. These hypoxia-induced IncRNAs have important functions in controlling tumour phenotypes, such as angiogenesis (106).

Accumulating evidence has shown that several hypoxia-induced IncRNAs regulate tumour angiogenesis and metastasis by modulating the HIF-1α signalling pathway. For example, Yang et al reported that IncRNA low expression in tumour (IncRNA-LET) was downregulated in hepatocellular carcinomas. Mechanistically, IncRNA-LET is suppressed under hypoxic conditions due to the activation of histone deacetylase 3 (HDAC3). IncRNA-LET was able to interact with nuclear factor 90 (NF90), which led to the degradation of NF90, therefore increasing HIF-1α under hypoxic conditions and leading to hypoxia-induced cancer cell invasion. Notably, IncRNA-LET downregulation was significantly correlated with tumour micrometastases in HCC (81). A similar result for IncRNA-LET as a prognostic marker for metastasis was also reported in primary gallbladder cancer (107). Another report showed that...
LncRNA-RERT downregulation was significantly correlated with HCC occurrence. LncRNA-RERT decreased the expression of HIF-1α by upregulating EGLN2 mRNA levels (108). In addition, two other lncRNAs, HIF1A-AS1 and HIF1A-AS2, which are antisense transcripts transcribed from the 3'-UTR of the sense HIF-1A mRNA negatively regulated HIF1A mRNA expression (109,110). Therefore, the association between HIF-1A mRNA levels and HIF1A-AS exhibits a negative feedback loop.

It has been well established that lncRNAs involved in the biological processes of HCC angiogenesis interact with the key angiogenesis regulators VEGF and HIF-1A and appear to be promising targets for anti-angiogenesis therapy. More novel lncRNA-associated angiogenesis and its mechanisms need to be identified and elucidated. Understanding the networks of interactions between lncRNAs and target genes may pave the way for new therapeutic strategies.

6. Conclusion and future perspectives

In this review, we have shown that, lncRNAs, acting as tumour suppressor genes or oncogenes, play an important role in HCC tumorigenesis and metastasis. Based on the corresponding relationships between lncRNAs, miRNAs and mRNAs, the regulatory relationships between lncRNAs and EMT, lncRNAs and HCC metastasis-related genes, lncRNAs and tumour angiogenesis were summarized. In these regulatory networks, once one of the important lncRNAs is out of balance, a chain reaction ultimately affects the relationship between multiple lncRNAs and several target genes of different pathways. Accordingly, with the identification of new lncRNAs associated with HCC metastasis, this regulatory network becomes increasingly complex. However, the molecular mechanism of HCC metastasis remains to be revealed more thoroughly. Based on current studies and additional lncRNAs that will be identified and verified in the future, lncRNAs may serve as novel diagnostic markers, prognostic markers and therapeutic targets.

Acknowledgements

Not applicable.

Funding

This review was supported by the Science and Technology Project of Zhejiang Province (2016KYA023, 2013RCA006, 2016ZA025, 2018KY466), the Natural Science Foundation of Zhejiang Province (LQ18H160025) and the National Natural Science Foundation of China (81572592).

Availability of data and materials

Not applicable.

Authors' contributions

LL and HP conceived the review. XZ and LL were involved in collecting the references, writing and reviewing the manuscript. XZ and LL were responsible for confirming the authenticity of all the raw data. The authors contributed to the final version.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

All authors consent to publication.

Competing interests

The authors declare that they have no competing interests.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
2. El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142: 1264-1273, 2012.
3. Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet 379: 1245-1255, 2012.
4. Bruix J and Sherman M; American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: An update. Hepatology 53: 1020-1022, 2011.
5. Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell 144: 646-674, 2011.
6. Ponting CP, Oliver PL and Reik W: Evolution and functions of long non-coding RNAs. Nature Rev Genet 17: 47-62, 2016.
7. Ulitsky I and Bartel DP: lincRNAs: Genomics, evolution, and mechanisms. Cell 154: 26-46, 2013.
8. Quinn JJ and Chang HY: Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet 17: 47-62, 2016.
9. Gutschner T, Hämmerle M, Eissmann M, Hsu J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, et al: The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res 73: 1180-1189, 2013.
10. Panzitt K, Tschernatsch MM, Guellcy C, Mostafau T, Stradner M, Strohmaier HM, Buck CR, Denk H, Schroeder R, Trauner M and Zatloukal K: Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 132: 330-342, 2007.
11. Nissan A, Stojadinovic A, Mitrani-Rosenbaum S, Halle D, Grinbaum R, Roistacher M, Bochem A, Dayanc BE, Ritter G, Gommelli L, et al: Colorectal cancer associated transcript-1: A novel RNA expressed in malignant and pre-malignant human tissues. Int J Cancer 130: 1598-1606, 2012.
12. Huarte M: The emerging role of lncRNAs in cancer. Nat Med 21: 1253-1261, 2015.
13. Wang Y, Chen F, Zhao M, Yang Z, Li J, Zhang S, Zhang W, Ye L and Zhang X: The long noncoding RNA HULC promotes liver cancer by increasing the expression of the HMGA2 oncogene via sequestration of the microRNA-186. J Biol Chem 292: 15395-15407, 2017.
14. He JH, Han ZP, Liu JM, Zhou JB, Zou MX, Lv YB, Li YG and Cao MR: Overexpression of long non-coding RNA MEG3 inhibits proliferation of hepatocellular carcinoma Huh7 cells via negative modulation of miRNA-664. J Cell Biochem 118: 3713-3721, 2017.
15. He Y, Meng XM, Huang C, Wu BM, Zhang L, Lv XW and Li J: Long noncoding RNAs: Novel insights into hepatocellular carcinoma. Cancer Letters 344: 20-27, 2014.
16. Gong X, Wei W, Chen L, Xia Z and Yu C: Comprehensive analysis of long non-coding RNA expression profiles in hepatitis B virus-related hepatocellular carcinoma. Oncotarget 7: 42422-42430, 2016.
17. Yang Y, Chen L, Gu J, Zhang H, Yuan J, Lian Q, Lv G, Wang S, Wu Y, Yang YT, et al: Recurrently deregulated IncRNAs in hepatocellular carcinoma. Nat Commun 8: 14421, 2017.
18. Li D, Liu X, Zhou J, Hu J, Zhang D, Liu J, Qiao Y and Zhan Q: Long noncoding RNA HULC modulates the phosphorylation of YB-1 through serving as a scaffold of extracellular signal-regulated kinase and YB-1 to enhance hepatocarcinogenesis. Hepatology 65: 1612-1627, 2017.
34. Nieto MA, Huang RY, Jackson RA and Thiery JP: EMT: 2016.
33. Lee JT: Epigenetic regulation by long noncoding RNAs.
35. Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, Liu F, Pan W, Chen F, Bai G, Li Y, Feng Y and Wang L: A positive feedback loop
39. Liu J, Lu C, Xiao M, Jiang F, Qu L and Ni R: Long non‑coding
40. Zhou M, Zhang XY and Yu X: Overexpression of the long
42. Zhang Y, Li Z, Zhang Y, Zhong Q, Chen Q and Zhang L: Molecular
36. Quagliata L, Matter MS, Piscuoglio S, Arabi L, Ruiz D, Procino A, du Y, Kong G, You X, Zhang T, Gao Y, Ye L and
38. RNA ccAT2 functions as an oncogene in hepatocellular carci‑
37. Wang TT, Zhou C, et al: Transcriptional regulatory mechanisms. cancer Metastasis Rev 28: 15‑33, 2009.
39. Long non‑coding RNA HULc: An oncogenic
40. non‑coding RNA in human cancer. J Cell Mol Med 21: 4077‑4090, 2017.
28. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial‑mesenchymal transitions in development and disease. Cell 139: 871‑890, 2009.
25. Yu X, Zhang H, Chen MT and Wu WK: HULc: An oncogenic
26. Yu X, Zhang H, Chen MT and Wu WK: HULc: An oncogenic
27. Moreno‑Bueno G, Portillo F and cano A: Transcriptional regulation
during cancer initiation and progression. Nat Rev cancer 13: 785‑797, 2013.
24. Lee JT: Epigenetic regulation by long noncoding RNAs. Science 338: 1435‑1439, 2012.
23. Cui M, Xiao Z, Wang Y, Zheng M, Song T, Cai X, Sun B, Ye L and Zhang X: Long noncoding RNA HULC modulates abnormal
lipid metabolism in hepatoma cells through an miR‑9‑mediated XRAA signaling pathway. Cancer Res 75: 846‑857, 2015.
22. Peinado H, Olmeda D and Cano A: Snail, Zeb1 and BHLH factors in tumour progression: An alliance against the epithelial‑phenotype? Nat Rev Cancer 7: 415‑428, 2007.
21. De Craene B and Berx G: Regulatory networks defining EMT and epithelial‑mesenchymal transition by sponging miR‑150‑5p. Mol Cancer 16: 123, 2017.
20. Wang Y, Liu Z, Yan X, Zhang L, Wu W, Wu S, Qian J, Hao Y, Yan F, Zhu P, Yan X, Zhang D, Wu W, Wu S, Qian J, Hao Y, Yan F, Zhu P, Wu J, Huang G, et al: Mesenchymal stem cells promote hepatocarcinogenesis via miR‑375‑5p and miR‑34a. Cancer Lett 382: 122‑132, 2017.
19. He T, Zhang L, Kong Y, Huang Y, Zhang Y, Zhou D, Zhou X, Yan Y, Zhang L, Li S, et al: Long non‑coding RNA CASC15 is upregulated in hepatocellular carcinoma and facilitates hepatocyte proliferation via regulating miR‑203. Oncol Lett 13: 1481‑900, 2017.
60. Jia M, Jiang L, Wang Yd, Huang JZ, Yu M and Xue HZ: Long non-coding RNA HOTAIR regulates cancer cell invasion and metastasis via epigenetic reprogramming of the X chromosome inactivation. Mol Cell 65: 137-147, 2017.

61. Gao K, Li X, Qin C and Li J: Prognostic value of VEGF in hepatocellular carcinoma. Clin Cancer Res 20: 1167-1172, 2014.

62. Ren YL, Shang JH, Li JL, Liu W, Zhang Z, Yuan J and Yang M: The long non-coding RNA CAT-1 links the microRNA miR-215 to oncogenic CRKL-mediated signaling in hepatocellular carcinoma. J Biol Chem 292: 17939-17949, 2017.

63. Yang F, Huo XS, Yuan SX, Zhang L, Zhou WP, Wang F and Shi JH: Repression of hepatic lncRNA-LET by histone deacetylase 3 contributes to hypoxia-mediated metastasis. Mol Cell 49: 1083-1096, 2013.

64. Wang M, Guo C, Wang L, Luo G, Huang C, Li Y, Liu D, Zeng F, Jiang G and Xiao X: Long noncoding RNA GAS5 promotes bladder cancer growth and metastasis through inhibiting EZH2 transcription. Cell Death Dis 9: 238, 2018.

65. Zhang Z, Zhu W, Watabe K, Zhang X, Bai C, Xu M, Wu F and Mo YY: Negative regulation of lncRNA GAS5 by miR-21. Cell Death Differ 20: 1558-1568, 2013.

66. Zhao XH, Wang P, Liu J, Zhang J, Liu Y, Chen J and Xue Y: Gas5 exerts tumor-suppressive functions in human glioma cells by targeting miR-222. Mol Ther 23: 1899-1911, 2015.

67. Li F, Yuan JH, Huang JF, Yang F, Wang TT, Ma JZ, Zhang L, Zhou CC, Wang F, Yu J, et al: Long noncoding RNA FTX inhibits hepatocellular carcinoma proliferation and metastasis by targeting miR-222 and miR-221. Oncotarget 35: 5422-5434, 2016.

68. Furlan G, Gutierrez Hernandez N, Huret C, Galupu R, van Bemmel JG, Romito A, Heard E, Morey C and Rougeulle C: The Fix noncoding locus controls X chromosome inactivation independently of its RNA products. Mol Cell 70: 462-472.e8, 2018.

69. Li H, Han B, Yang X, Ma Y, Zhao QY, Wu Q and Li Q: MicroRNA-92b promotes hepatocellular carcinoma progression by targeting Smad7 and is mediated by long non-coding RNA XIST. Cell Death Dis 7: e2303, 2016.

70. Chang SZ, Chen BH, Wang XY, Wu KQ and Sun YQ: Long non-coding RNA XIST regulates PTEN expression by sponging miR-181a and promotes hepatocellular carcinoma progression. BMC Cancer 14: 2017.

71. Kong Q, Zhang S, Liang C, Zhang Y, Kong Q, Chen S, Jin J and Jin Y: IncRNA XIST functions as a molecular sponge of miR-194-5p to regulate MAPK1 expression in hepatocellular carcinoma cell. J Cell Biochem 119: 4458-4468, 2018.

72. Malakar P, Shilo A, Mogilevsky A, Stein I, Pikarsky E, Nevo Y, Benyamini H, Elgavish S, Zong X, Prasanth KV and Karni R: Long non-coding RNA MALAT1 regulates ZEB1 expression by sponging miR-143-3p and promotes hepatocellular carcinoma progression. J Cell Mol Med 12: 2189-2204, 2008.

73. Deng Y, Miao R, Liu S, Wan Y, Zhang S, Deng Y, Bi J, Qu K and Zhang J: ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma patients treated with Sorafenib: A meta-analysis. Med Sci Monit 23: 1844-3151, 2017.

74. Fu WM, Lu YF, Hu BG, Liang WC, ZHU X, Yang HD, Li G and Zhang JF: Long noncoding RNA Hotair mediated angiogenesis in nasopharyngeal carcinoma by direct and indirect signaling pathways. Oncotarget 7: 4712-4723, 2016.

75. Ma X, Li Z, Li T, Zhu L and Tian N: Long non-coding RNA HOTAIR enhances angiogenesis by induction of VEGF expression in glioma cells and transmission to endothelial cells via glioma cell-derived extracellular vesicles. Am J Transl Res 9: 3503-3821, 2017.

76. Seo WY, Xie W, Shang Q and Su B: The long noncoding RNA MEG3 is downregulated and inversely associated with vegf levels in osteoarthritis. Biomed Res Int 2015: 356893, 2015.
100. Zhan R, Xu K, Pan J, Xu Q, Xu S and Shen J: Long noncoding RNA MEG3 mediated angiogenesis after cerebral infarction through regulating p53/NOX4 axis. Biochem Biophys Res Commun 490: 700-706, 2017.

101. Liu L, Chen X, Zhang Y, Hu Y, Shen X and Zhu W: Long non-coding RNA TUG1 promotes endometrial cancer development via inhibiting miR-299 and miR-34a-5p. Oncotarget 8: 31386-31394, 2017.

102. Jiang Q, Shan K, Qun-Wang X, Zhou RM, Yang H, Liu C, Li YJ, Yao J, Li XM, Shen Y, et al: Long non-coding RNA-MIAT promotes neurovascular remodeling in the eye and brain. Oncotarget 7: 49688-49698, 2016.

103. Li X, Song Y, Liu F, Liu D, Miao H, Ren J, Xu J, Ding L, Hu Y, Wang Z, et al: Long non-coding RNA MALAT1 promotes proliferation, angiogenesis, and immunosuppressive properties of mesenchymal stem cells by inducing VEGF and IDO. J Cell Biochem 118: 2780-2791, 2017.

104. Zhu Y, Zhang X, Qi L, Cai Y, Yang P, Xuan G and Jiang Y: HULC long noncoding RNA silencing suppresses angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling pathway in human gliomas. Oncotarget 7: 14429-14440, 2016.

105. Xiao H, Tong R, Cheng S, Lv Z, Ding C, Du C, Xie H, Zhou L, Wu J and Zheng S: BAG3 and HIF-1 alpha coexpression detected by immunohistochemistry correlated with prognosis in hepatocellular carcinoma after liver transplantation. Biomed Res Int 2014: 516518, 2014.

106. Takahashi K, Yan IK, Haga H and Patel T: Modulation of hypoxia-signaling pathways by extracellular linc-RoR. J Cell Sci 127: 1585-1594, 2014.

107. Zhuang J, Shen L, Yang L, Huang X, Lu Q, Cui Y, Zheng X, Zhao X, Zhang D, Huang R, et al: TGFβ1 promotes gemcitabine resistance through regulating the lncRNA-LET/NF90/miR-145 signaling axis in bladder cancer. Theranostics 7: 3053-3067, 2017.

108. Zhu Z, Gao X, He Y, Zhao H, Yu Q, Jiang D, Zhang P, Ma X, Huang H, Dong D, et al: An insertion/deletion polymorphism within RERT-lncRNA modulates hepatocellular carcinoma risk. Cancer Res 72: 6163-6172, 2012.

109. Mineo M, Ricklefs F, Rooy AK, Lyons SM, Ivanov P, Ansari KI, Nakano I, Chiocca EA, Godlewski J and Bronisz A: The long non-coding RNA HIF1A-AS2 facilitates the maintenance of mesenchymal glioblastoma stem-like cells in hypoxic Niches. Cell Rep 15: 2500-2509, 2016.

110. Wang J, Chen L, Li H, Yang J, Gong Z, Wang B and Zhao X: Clopidogrel reduces apoptosis and promotes proliferation of human vascular endothelial cells induced by palmitic acid via suppression of the long non-coding RNA HIF1A-AS1 in vitro. Mol Cell Biochem 404: 203-210, 2015.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.